Clinical Scorecard: Fluorescent Imaging Demystifies Melanoma

At a Glance

Key Highlights

• SFI system shows 100% detection of oncogenic activity in melanoma cases.
• AUC of 0.907 indicates solid discriminatory performance for lesion triage.
• SFI provides molecular information that complements visual assessment.
• Potential to reduce unnecessary biopsies and identify aggressive cancers early.
• Higher sensitivity and specificity compared to traditional dermoscopy.

Guideline-Based Recommendations

Diagnosis

• Utilize SFI for non-invasive assessment of atypical pigmented lesions.

Management

• Biopsy lesions with high SFI scores indicating high likelihood of melanoma.

Monitoring & Follow-up

• Monitor lesions without evidence of tissue remodeling activity.

Risks

• Risk of misclassification of lesions without SFI assessment.

Patient & Prescribing Data

Individuals with atypical pigmented lesions.

SFI can guide treatment decisions based on molecular activity.

Clinical Best Practices

• Incorporate SFI alongside ABCDE criteria for lesion evaluation.
• Use SFI to inform biopsy decisions and reduce unnecessary procedures.
• Consider SFI results in conjunction with patient history and visual assessments.

References

• JAAD International Study